+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compound muscle action potential and motor function in children with spinal muscular atrophy

Compound muscle action potential and motor function in children with spinal muscular atrophy

Muscle and Nerve 42(5): 703-708

Reliable outcome measures that reflect the underlying disease process and correlate with motor function in children with SMA are needed for clinical trials. Maximum ulnar compound muscle action potential (CMAP) data were collected at two visits over a 4-6-week period in children with SMA types II and III, 2-17 years of age, at four academic centers. Primary functional outcome measures included the Modified Hammersmith Functional Motor Scale (MHFMS) and MHFMS-Extend. CMAP negative peak amplitude and area showed excellent discrimination between the ambulatory and non-ambulatory SMA cohorts (ROC = 0.88). CMAP had excellent test-retest reliability (ICC = 0.96-0.97, n = 64) and moderate to strong correlation with the MHFMS and MHFMS-Extend (r = 0.61-0.73, n = 68, P < 0.001). Maximum ulnar CMAP amplitude and area is a feasible, valid, and reliable outcome measure for use in pediatric multicenter clinical trials in SMA. CMAP correlates well with motor function and has potential value as a relevant surrogate for disease status.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052269184

Download citation: RISBibTeXText

PMID: 20737553

DOI: 10.1002/mus.21838

Related references

Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. European Journal of Paediatric Neurology 5(5): 191-198, 2001

Increasing Agrin Function Antagonizes Muscle Atrophy and Motor Impairment in Spinal Muscular Atrophy. Frontiers in Cellular Neuroscience 12: 17, 2018

Motor function-muscle strength relationship in spinal muscular atrophy. Muscle and Nerve 29(4): 548-552, 2004

Discrepancy between decreases in the amplitude of compound muscle action potential and loss of motor function caused by ischemic and compressive insults to the spinal cord. Journal of Orthopaedic Science 7(1): 102-110, 2002

Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. European Journal of Neurology 25(3): 512-518, 2017

Correlations between change scores of measures for muscle strength and motor function in individuals with spinal muscular atrophy types 2 and 3. American Journal of Physical Medicine and Rehabilitation 92(4): 335-342, 2013

Transcranial motor-evoked potentials combined with response recording through compound muscle action potential as the sole modality of spinal cord monitoring in spinal deformity surgery. Spine 33(10): 1100-1106, 2008

Evaluation of therapeutic electrical stimulation to improve muscle strength and function in children with types II/III spinal muscular atrophy. Developmental Medicine & Child Neurology 44(11): 741-744, 2002

The effect of anesthetic agents on descending spinal cord evoked potential and the compound muscle action potentials elicited by stimulation at the cerebral motor cortex and the spinal cord. Nihon Seikeigeka Gakkai Zasshi 66(4): 279-290, 1992

Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy. Bmc Medicine 11: 38, 2014

Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345(6197): 688-693, 2014

High incidence of a survival motor neuron gene/cBCD541 gene ratio of 2 in Japanese parents of spinal muscular atrophy patients: A characteristic background of spinal muscular atrophy in Japan?. Journal of Neurology 246(1): 48-52, 1999

Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Advances in Therapy 2019, 2019

Sanger sequencing for the diagnosis of spinal muscular atrophy patients with survival motor neuron gene 1 compound heterozygous mutation. Zhonghua Yi Xue Za Zhi 97(6): 418-423, 2018

Spinal motoneuron function in lower motor neuron disease: normal corticomotoneuronal and peripheral Ia EPSPs in patients with spinal muscular atrophy. Electromyography and Clinical Neurophysiology 39(1): 27-32, 1999